explore -WSS

explore

author：entertainment 2025-10-01 10:36:20 - browse：3

Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill. -- health policy coverage from STAT — Sen. Ron Wyden, D-Ore., left, and Sen. Mike Crapo, R-Idaho, right, walk on Capitol Hill in 2021. Susan Walsh/AP

WASHINGTON — One of the top health care committees in the Senate is assembling ideas for bipartisan legislation to address drug shortages, three Senate aides and three lobbyists told STAT.

The talks, led by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) are in the early days, but they could move the debate over drug shortage reforms into a new phase. The committee has jurisdiction over Medicare and Medicaid payment policies for hospitals. Other committees that have tried tackling the issue have jurisdiction mostly over the Food and Drug Administration.

The panel is tentatively aiming to hold a hearing on the issue in November, the sources said. The panel has also started accepting input from outside stakeholders, one lobbyist said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout LOUD podcast: How biotech is using artificial intelligence

WSS

Maui funeral service workers on devastation of fires: 'I'm in shock'

Large hospital system sues Multiplan for low

Robert F. Kennedy is pitching centrism on health, even on abortion

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Genentech weighs delaying cancer therapy after drug pricing law

Who are the detained American citizens released from prison in Iran?

focus

explore

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

To avoid data mishandling cases, universities eye AI and other tools

Guidelines to prevent youth baseball injuries need more muscle

Gilead might be held responsible for not developing a drug

After affirmative action ruling, medical educators look to 'holistic review'

How digital tools helped lower hypertension in marginalized patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

To avoid data mishandling cases, universities eye AI and other tools

Bright Health sells Medicare Advantage business to Molina

For Medicare Advantage, Democrats want stronger protections around AI

knowledge

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Biogen Alzheimer’s drug launch off to slow start

PhRMA lawsuit over Medicare drug price negotiation tossed

The dental labor crisis is a moment of opportunity

Newly revealed memo details efforts to keep Trump in power following election loss

Industry veterans launch new biotech VC with $310M

Wikipedia

focus

Wikipedia

leisure time